India's CSIR Launches Ayurvedic Drug Against Diabetes

Posted: Jun 27 2016, 9:27am CDT | by , in News | Latest Science News

 

India's CSIR Launches Ayurvedic Drug against Diabetes
Photo Credit: Getty Images
 

The Council for Scientific and Industrial Research (CSIR) on Monday launched its Ayurvedic anti-diabetic drug BGR-34.

Aimed at managing type 2 diabetes, BGR-34 has been jointly developed by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), both located in Lucknow.

"The modern diabetes drugs are known for side-effects and toxicity while BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs," said NBRIs' Senior Principal Scientist A.K.S. Rawat.

NBRI and CIMAP scientists studied nearly 500 ancient herbs listed in Ayurvedic texts to zero in on daruharidra (Berberis aristata), giloy (Tinospora cordifolia), vijaysar (Pterocarpus marsupium), gudmar (Gymnema sylvestre), majeeth (Rubia cordifoila) and methika (Trigonella foenum-graecum) to make the anti-diabetic formulation.

Ayurvedic pharma compnay AIMIL Pharmaceuticals will commercially produce and distribute BGR- 34, which has been priced at Rs 5 and will be available widely across Karnataka and neighboring states.

"BGR-34 is a unique product that manages the lives of human suffering diabetics. The product passed several battery of tests and showed hypoglycemic activity in experimental subjects," said AIMIL Pharmaceuticals vice president Anil Kumar Sharma.

This story may contain affiliate links.

Comments

The Author

<a href="/latest_stories/all/all/59" rel="author">IANS</a>
The Indo-Asian News Service (IANS) was established in 1986, initially to serve as an information bridge between India and its thriving Diaspora in North America. Now IANS is a full-fledged wire agency, putting out news 24x7 from around the world.

 

 

Advertisement

comments powered by Disqus